Price List Atopy - Atopy-IL-13 IL-31.xlsx

XLSX spreadsheet 46 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Solicitation number
HT9402-25-Q-9301
Issued by

About this file

This is a Price List for a Department of Defense (DoD) Uniform Formulary Blanket Purchase Agreement (BPA) for pharmaceutical agents in the Atopy drug class, specifically targeting IL-13 and IL-31 subclasses. The solicitation (HT9402-25-Q-9301) is issued by the Defense Health Agency for the August 2025 Pharmacy and Therapeutics (P&T) Committee Meeting, with quotes due on June 26, 2025. The document outlines complex pricing and formulary scenarios for potential pharmaceutical agents, including provisions for Uniform Formulary (UF) placement, step therapy requirements, and retail refund structures.

Key details include potential prior authorization requirements, special reimbursement methods, and the possibility of preferential status or exclusion from the TRICARE pharmacy benefit program. The BPA includes multiple appendices covering different formulary scenarios for both Military Treatment Facilities/Mail Order and TRICARE Retail channels, with specific condition sets for one or more agents. Manufacturers are required to submit fully executed signature pages with quote information, and the pricing mechanism involves calculations based on non-Federal Average Manufacturer Price (non-FAMP) and Federal Ceiling Price (FCP) with additional offered refunds.

View the file

Other files

File Type Posted
Price List Diuretics - Mineralocorticoid Receptor Antagonists.xlsx XLSX spreadsheet
August 2025 PT Meeting Reporting.xlsx XLSX spreadsheet
NDC Price List FAQ Class Review.pdf PDF
RFQ HT9402-25-Q-9301 CR.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the August 2025 DoD P&T Meeting
DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
Formulary Notes

Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a PA process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service. There will be no grandfathering between biosimilar products.

All Scenarios:

• Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).

• Specialist bypass and/or drug auto-lookback may be considered for the step-preferred agent.

• The P&T Committee may consider a step preference for the Atopic Dermatitis indication, and all other indications would not have a step.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Class Review

#1DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#2DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#3DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#4DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#5DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
1.00
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy11.00NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or more1.00NO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or more1.00NO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or more1.00NO QUOTE
254ATAIG1NF1MNon-Formulary1 or more1.00NO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#6DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#7DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#8DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#9DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Class Review

#10DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step
Scenario 1254ATAIG1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
254ATAIG1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
254ATAIG1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF
Scenario 2254ATAIG1UF1MUniform Formulary1 or moreNO QUOTE
254ATAIG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Appendix for the August 2025 DoD P&T Meeting
DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
Formulary Notes

Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a PA process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service. There will be no grandfathering between biosimilar products.

All Scenarios:

• Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).

• Specialist bypass and/or drug auto-lookback may be considered for the step-preferred agent.

• The P&T Committee may consider a step preference for the Atopic Dermatitis indication, and all other indications would not have a step.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Class Review

#1DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#2DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#3DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#4DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#5DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#6DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#7DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#8DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#9DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Class Review

#10DOD Uniform Formulary Class:ATOPYP&T Committee Meeting:August 6-7, 2025
DOD Uniform Formulary Subclass:ATOPY: IL-13, IL-31Quotes due:June 26, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Branded AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step
Scenario 1254ATAIG1T2BS1Tier 2
Before Step Therapy1
254ATAIG1T2AS1MTier 2
After Step Therapy1 or more
254ATAIG1T3AS1MTier 3
After Step Therapy1 or more
Scenario 2: One or more agents T2
Scenario 2254ATAIG1T21MTier 21 or more
254ATAIG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .